Author

Katjuša Koler

Artios Pharma Limited (United Kingdom)ORCID 0000-0001-8624-9488Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Alessandro CicconiiD· 1 shared Asmita Thapa· 1 shared Aurora CeruttiiD· 1 shared Bethany Rebekah Hill· 1 shared Célia GotorbeiD· 1 shared David NderituiD· 1 shared Eeson RajendraiD· 1 shared Geoff Stuart HigginsiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alessandro CicconiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy

Gonzalo Rodríguez‐Berriguete, Purusotha Thambiayah, Alessandro Cicconi, Nicole Machado, Célia Gotorbe, David Nderitu, Wei‐Chen Cheng, Gerissa Fowler, Marie Laure Boursier, Aurora Cerutti, Vera V. Grinkevich, Bethany Rebekah Hill, Katjuša Koler, Sophie Alice Langdon, Jayesh B. Majithiya, , Geoff Stuart Higgins

The paper identifies SHLD2 loss as a vulnerability that enhances radiosensitisation when combined with Polθ inhibition in cancer cells.

Science Advances · Jun 12, 2026Peer-reviewedCancer Biology